Drug
Granulocyte Colony Stimulating Factor
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Mucosal Inflammation | 139 | 51.5 | 55.0 | signal |
| 2 | Cytomegalovirus Infection | 87 | 50.5 | 52.6 | signal |
| 3 | Febrile Neutropenia | 333 | 48.6 | 57.2 | signal |
| 4 | Haematotoxicity | 35 | 36.4 | 37.0 | signal |
| 5 | Bone Marrow Failure | 65 | 30.6 | 31.5 | signal |
| 6 | Acute Myeloid Leukaemia | 33 | 20.4 | 20.7 | signal |
| 7 | Bacteraemia | 23 | 18.8 | 19.0 | signal |
| 8 | Myelodysplastic Syndrome | 28 | 18.6 | 18.9 | signal |
| 9 | Neutrophil Count Increased | 18 | 16.9 | 17.0 | signal |
| 10 | Pneumocystis Jirovecii Pneumonia | 16 | 15.4 | 15.5 | signal |
| 11 | Neutropenia | 216 | 15.4 | 16.9 | signal |
| 12 | Thrombotic Microangiopathy | 15 | 14.9 | 15.0 | signal |
| 13 | Lymphopenia | 20 | 13.7 | 13.8 | signal |
| 14 | Clostridium Difficile Colitis | 15 | 13.6 | 13.7 | signal |
| 15 | Septic Shock | 57 | 12.7 | 13.0 | signal |
| 16 | Thrombocytopenia | 143 | 12.3 | 13.1 | signal |
| 17 | Disseminated Intravascular Coagulation | 18 | 12.3 | 12.4 | signal |
| 18 | Sepsis | 140 | 12.1 | 12.8 | signal |
| 19 | Lung Infection | 19 | 11.6 | 11.7 | signal |
| 20 | Nephropathy Toxic | 12 | 10.4 | 10.4 | signal |
| 21 | Pancytopenia | 58 | 10.0 | 10.3 | signal |
| 22 | Multiple Organ Dysfunction Syndrome | 29 | 10.0 | 10.1 | signal |
| 23 | Interstitial Lung Disease | 50 | 10.0 | 10.2 | signal |
| 24 | Multi-organ Failure | 18 | 9.9 | 9.9 | signal |
| 25 | Respiratory Failure | 71 | 9.4 | 9.6 | signal |
| 26 | Candida Infection | 15 | 8.6 | 8.7 | signal |
| 27 | Neutrophil Count Decreased | 36 | 8.6 | 8.7 | signal |
| 28 | Posterior Reversible Encephalopathy Syndrome | 8 | 8.1 | 8.1 | signal |
| 29 | Generalised Oedema | 10 | 7.8 | 7.8 | signal |
| 30 | Bacterial Infection | 15 | 7.8 | 7.8 | signal |
| 31 | Product Use In Unapproved Indication | 191 | 7.5 | 8.1 | signal |
| 32 | Blood Bilirubin Increased | 20 | 7.1 | 7.2 | signal |
| 33 | Hypomagnesaemia | 10 | 6.9 | 7.0 | signal |
| 34 | Neoplasm Progression | 25 | 6.9 | 6.9 | signal |
| 35 | Pneumonitis | 19 | 6.8 | 6.8 | signal |
| 36 | Leukopenia | 35 | 6.7 | 6.8 | signal |
| 37 | Splenomegaly | 8 | 6.6 | 6.6 | signal |
| 38 | Ascites | 20 | 6.5 | 6.6 | signal |
| 39 | Disease Progression | 80 | 6.5 | 6.7 | signal |
| 40 | Cytopenia | 8 | 6.4 | 6.5 | signal |
| 41 | Agranulocytosis | 12 | 6.2 | 6.3 | signal |
| 42 | Oesophagitis | 7 | 6.2 | 6.2 | signal |
| 43 | Infection | 92 | 6.1 | 6.4 | signal |
| 44 | Respiratory Disorder | 19 | 6.1 | 6.1 | signal |
| 45 | Acute Respiratory Distress Syndrome | 11 | 6.0 | 6.0 | signal |
| 46 | Fluid Overload | 9 | 5.9 | 5.9 | signal |
| 47 | Haemorrhage Intracranial | 9 | 5.8 | 5.8 | signal |
| 48 | Polyneuropathy | 7 | 5.7 | 5.7 | signal |
| 49 | Disease Recurrence | 28 | 5.6 | 5.7 | signal |
| 50 | Hepatotoxicity | 13 | 5.6 | 5.7 | signal |
| 51 | Neurotoxicity | 10 | 5.5 | 5.6 | signal |
| 52 | Staphylococcal Infection | 19 | 5.5 | 5.6 | signal |
| 53 | Stomatitis | 33 | 5.2 | 5.3 | signal |
| 54 | Gamma-glutamyltransferase Increased | 12 | 5.2 | 5.2 | signal |
| 55 | Intestinal Perforation | 6 | 5.1 | 5.1 | signal |
| 56 | Status Epilepticus | 6 | 5.1 | 5.1 | signal |
| 57 | Platelet Count Decreased | 56 | 5.1 | 5.2 | signal |
| 58 | Pericardial Effusion | 12 | 5.0 | 5.0 | signal |
| 59 | Drug Resistance | 13 | 4.9 | 4.9 | signal |
| 60 | Transaminases Increased | 11 | 4.8 | 4.8 | signal |
| 61 | Skin Lesion | 13 | 4.6 | 4.6 | signal |
| 62 | Hepatic Failure | 14 | 4.5 | 4.5 | signal |
| 63 | Clostridium Difficile Infection | 10 | 4.4 | 4.5 | signal |
| 64 | Hepatic Function Abnormal | 17 | 4.4 | 4.4 | signal |
| 65 | Lymphoma | 7 | 4.3 | 4.4 | signal |
| 66 | Abscess | 7 | 4.2 | 4.2 | signal |
| 67 | Blood Lactate Dehydrogenase Increased | 7 | 4.2 | 4.2 | signal |
| 68 | Squamous Cell Carcinoma | 4 | 4.1 | 4.1 | signal |
| 69 | No Therapeutic Response | 5 | 3.9 | 3.9 | signal |
| 70 | Therapy Partial Responder | 6 | 3.8 | 3.8 | signal |
| 71 | White Blood Cell Count Decreased | 43 | 3.8 | 3.9 | signal |
| 72 | Hypothermia | 4 | 3.8 | 3.8 | signal |
| 73 | Cerebral Haemorrhage | 14 | 3.8 | 3.8 | signal |
| 74 | Gingival Bleeding | 5 | 3.5 | 3.5 | signal |
| 75 | Drug Level Increased | 6 | 3.5 | 3.5 | signal |
| 76 | Malignant Neoplasm Progression | 32 | 3.0 | 3.1 | signal |
| 77 | Malignant Melanoma | 4 | 2.9 | 2.9 | no signal |
| 78 | Premature Baby | 9 | 2.9 | 2.9 | signal |
| 79 | Full Blood Count Decreased | 6 | 2.9 | 2.9 | signal |
| 80 | Drug Effect Incomplete | 10 | 2.6 | 2.6 | signal |
| 81 | Palmar-plantar Erythrodysaesthesia Syndrome | 6 | 2.5 | 2.5 | no signal |
| 82 | Plasma Cell Myeloma | 10 | 2.5 | 2.5 | signal |
| 83 | Drug Toxicity | 3 | 2.1 | 2.1 | no signal |
| 84 | Hepatocellular Injury | 3 | 2.0 | 2.0 | no signal |
| 85 | Hepatic Cancer | 5 | 2.0 | 2.0 | no signal |
| 86 | Myelosuppression | 6 | 1.7 | 1.7 | no signal |
| 87 | Foetal Exposure During Pregnancy | 12 | 1.4 | 1.4 | no signal |